Rigel Pharmaceuticals (RIGL) Net Margin (2010 - 2026)

Rigel Pharmaceuticals' Net Margin history runs 16 years deep, the most recent figure standing at 14.71% for Q1 2026.

• In Q1 2026, Net Margin fell 675.0% year-over-year to 14.71%; the TTM figure through Mar 2026 stood at 121.51% (up 10320.0% YoY), while the FY2025 annual figure was 124.72%, up 11497.0% from the prior year.
• Net Margin was 14.71% for Q1 2026 at Rigel Pharmaceuticals, down from 384.04% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 384.04% in Q4 2025 to a low of 164.0% in Q1 2022.
• Historically, Net Margin has averaged 8.8% across 5 years, with a median of 2.06% in 2023.
• The sharpest annual moves came in 2022 and 2025: Net Margin tumbled 21275 bps in 2022, then surged 35914 bps in 2025.
• A 5-year view of Net Margin shows it stood at 2.73% in 2022, then declined by 25 bps to 2.06% in 2023, then surged by 1109 bps to 24.9% in 2024, then soared by 1442 bps to 384.04% in 2025, then plunged by 96 bps to 14.71% in 2026.
• The last three Net Margin figures came in at 14.71% (Q1 2026), 384.04% (Q4 2025), and 40.17% (Q3 2025), per Business Quant data.